Pulmonx Corp - Asset Resilience Ratio
Pulmonx Corp (LUNG) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Pulmonx Corp's Asset Resilience Ratio has changed over time. Check Pulmonx Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pulmonx Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pulmonx Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Pulmonx Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Pulmonx Corp Industry Peers by Asset Resilience Ratio
Compare Pulmonx Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO |
Medical Devices | 10.80% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Pulmonx Corp (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Pulmonx Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $129.29 Million | -- |
| 2024-12-31 | 18.78% | $30.58 Million | $162.85 Million | -0.10pp |
| 2023-12-31 | 18.87% | $33.55 Million | $177.78 Million | -1.47pp |
| 2022-12-31 | 20.34% | $39.40 Million | $193.68 Million | +6.92pp |
| 2021-12-31 | 13.42% | $31.56 Million | $235.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $263.71 Million | -- |
| 2019-12-31 | 25.37% | $13.58 Million | $53.53 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $15.01 Million | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more